Literature DB >> 17920040

Celecoxib transiently inhibits cellular protein synthesis.

Peter Pyrko1, Adel Kardosh, Axel H Schönthal.   

Abstract

To uncover the full spectrum of its pharmacological activities, the selective COX-2 inhibitor celecoxib is routinely being used at concentrations of up to 100 microM in cell culture. At these elevated concentrations, several COX-2-independent effects were identified, although many details of these events have remained unclear. Here, we report a COX-2-independent effect of celecoxib that might have profound consequences for the interpretation of previous results obtained at elevated concentrations of this drug in vitro. We found that celecoxib rapidly inhibits general protein translation at concentrations as low as 30 microM. This appears to be a consequence of endoplasmic reticulum (ER) stress and entails the phosphorylation and inactivation of eukaryotic translation initiation factor 2 alpha (eIF2alpha). These effects were not achieved by other coxibs (rofecoxib, valdecoxib) or traditional NSAIDs (indomethacin, flurbiprofen), but were mimicked by the COX-2-inactive celecoxib analog, 2,5-dimethyl-celecoxib (DMC), indicating COX-2 independence. Considering the obvious impact of blocked translation on cellular function, we provide evidence that this severe inhibition of protein synthesis might suffice to explain some of the previously reported COX-2-independent effects of celecoxib, such as the down-regulation of the essential cell cycle regulatory protein cyclin D, which is a short-lived protein that rapidly disappears in response to the inhibition of protein synthesis. Taken together, our findings establish ER stress-induced inhibition of general translation as a critical outcome of celecoxib treatment in vitro, and suggest that this effect needs to be considered when interpreting observations from the use of this drug in cell culture.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920040     DOI: 10.1016/j.bcp.2007.08.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.

Authors:  You-Take Oh; Xiangguo Liu; Ping Yue; Sumin Kang; Jing Chen; Jack Taunton; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

3.  The deadly connection between endoplasmic reticulum, Ca2+, protein synthesis, and the endoplasmic reticulum stress response in malignant glioma cells.

Authors:  Guyla G Johnson; Misti C White; Jian-He Wu; Matthew Vallejo; Maurizio Grimaldi
Journal:  Neuro Oncol       Date:  2014-02-24       Impact factor: 12.300

4.  WJ9708012 exerts anticancer activity through PKC-α related crosstalk of mitochondrial and endoplasmic reticulum stresses in human hormone-refractory prostate cancer cells.

Authors:  Ting-chun Kuo; Wei-jan Huang; Jih-hwa Guh
Journal:  Acta Pharmacol Sin       Date:  2010-12-06       Impact factor: 6.150

5.  Inhibition of secretion of interleukin (IL)-12/IL-23 family cytokines by 4-trifluoromethyl-celecoxib is coupled to degradation via the endoplasmic reticulum stress protein HERP.

Authors:  Martin McLaughlin; Iraide Alloza; Hung Pham Quoc; Christopher J Scott; Yasuhiko Hirabayashi; Koen Vandenbroeck
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

6.  Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection.

Authors:  Matthew P Bernard; Simona Bancos; Timothy J Chapman; Elizabeth P Ryan; John J Treanor; Robert C Rose; David J Topham; Richard P Phipps
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

Review 7.  Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy.

Authors:  A H Schönthal
Journal:  Br J Cancer       Date:  2007-10-23       Impact factor: 7.640

8.  COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.

Authors:  Huan-Ching Chuang; Adel Kardosh; Kevin J Gaffney; Nicos A Petasis; Axel H Schönthal
Journal:  Mol Cancer       Date:  2008-05-16       Impact factor: 27.401

9.  In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines.

Authors:  H Sadeghi-Aliabadi; M Aliasgharluo; A Fattahi; M Mirian; M Ghannadian
Journal:  Res Pharm Sci       Date:  2013-10

10.  COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.

Authors:  Evrim Gurpinar; William E Grizzle; Gary A Piazza
Journal:  Front Oncol       Date:  2013-07-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.